• Tel. 900 101 549
  • +34 93 546 01 35
  • Facebook IOR
  • Twitter IOR
  • LinkedIn IOR
  • Hospital Universitari Dexeus
  • Centro Médico Teknon
  • Hospital Universitari General de Cataluña
  • Hospital Universitari Sagrat Cor

SCIENTIFIC PUBLICATIONS

Our medical oncologists and laboratory investigators are at the forefront of investigations into the causes of cancer and the search for novel treatments.

We have published the results of our investigations, often in collaboration with some of the most prestigious international institutions, in renowned medical journals such as the New England Journal of Medicine, Clinical Cancer Research, and many others.

CONSULT OUR SCIENTIFIC PUBLICATIONS

01/09/2015

Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression

AUTHORS Bosch-Barrera J, Holguin F, Baldó X, Rubio M, Porta R, Fuentes R, Teixidó C, Ramirez JL, Ferran N, Sebastián F, Rosell R.

PUBLICATION Anticancer Res. 2015 Sep;35(9):4871-5.

READ ARTICLE

01/08/2015

A Randomized Phase 2 Study Of Ganetespib, A Heat Shock Protein 90 Inhibitor, In Combination With Docetaxel in Second-Line Therapy Of Advanced Non-Small-Cell Lung Cancer (GALAXY-1)

AUTHORS Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Samarzija B, Felip E, Ciuleanu T-E, Hirsh V, Wehler T, Spicer J, Salgia R, Shapiro G, Sheldon E, Teofilovici F, Vukovic V, Fennell D.

PUBLICATION Ann Oncol (2015) Aug;26(8):1741-8

READ ARTICLE

01/08/2015

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer

AUTHORS Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG.

PUBLICATION Nat Med. 2015 Sep;21(9):1038-47. Epub 2015 Aug 24.

READ ARTICLE

01/06/2015

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis

AUTHORS Khoon Lee C, Wu Y-L, Ni Ding P, Lord S, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla R, Chih-Hsin Yang J. J

PUBLICATION Clin Oncol 2015 Jun 10;33(17):1958-65

READ ARTICLE

01/05/2015

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

AUTHORS Karachaliou K, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, Garcia-Gomez R, Massuti B, Sánchez J.M, Porta R, Ponce-Aix S, Moran T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano J.L, Molina-Vila M.A, Rosell R.

PUBLICATION JAMA Oncology 2015; 1(2):149-157

READ ARTICLE